Omada Health IPO to Price at $19 a Share as GLP-1s Fuel Interest
The virtual healthcare platform on Friday will start trading publicly after 14 years of providing support to patients with weight-related chronic illnesses. Leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such as Ozempic, Wegovy and Mounjaro have sparked renewed focus on health problems that can stem from obesity, President Wei-Li Shao said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Bio-Techne Announces Exosome Diagnostics Divestiture
MINNEAPOLIS, Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar. "Mdxhealth is the ideal acquirer of our ExoDx Prostate test and CLIA-certified laboratory," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Mdxhealth has made several strategic moves over the past few years to position the company as a leader in urology and prostate cancer diagnostics. The addition of ExoDx Prostate to their portfolio accelerates their leadership in this market." Kelderman continued, "Following this transaction, Bio-Techne will strengthen its foundation as a developer of innovative, high value, high margin products, tools and reagents for the life science research and clinical diagnostics markets. This repositioning of the portfolio enables Bio-Techne to direct additional investments to further strengthen this foundation, while creating an immediate uplift to our sector leading operating margin profile." "ExoDx Prostate is a strong strategic fit with our rapidly growing urology and prostate cancer diagnostic business," said Michael McGarrity, Chief Executive Officer of Mdxhealth. "The ExoDx Prostate test equips men with information to make better decisions and avoid unnecessary and potentially dangerous prostate biopsies. Bio-Techne has done a tremendous job delivering this necessary information to patients and growing the base of physicians leveraging this tool. We are looking forward to building on this success." Under the terms of the agreement, Bio-Techne will receive $5 million in MDXH stock combined with future considerations. The transaction is expected to be completed during the first quarter of Bio-Techne's fiscal 2026. Bio-Techne will discuss this transaction, as well as its fourth quarter fiscal 2025 performance on its earnings call tomorrow, August 6th, 2025, at 8:00 a.m. CDT. To listen, please dial 1-800-274-8461 or 1-203-518-9814 (for international callers), and reference conference ID: TECHQ4. The earnings call can also be accessed via webcast through the following link Forward Looking Statements: Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding our belief about the impact of our pending divestiture of Exosome Diagnostics Inc. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements. About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,000 employees worldwide. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About mdxhealth®Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in Irvine, California, with additional laboratory operations in Plano, Texas. For more information, visit and follow us on social media at: and For more information:info@ LifeSci Advisors (IR & PR)John FrauncesManaging DirectorTel: +1 917 355 2395Jfraunces@ ir@ View original content to download multimedia: SOURCE Bio-Techne Corporation
Fox News
28 minutes ago
- Fox News
Trump's quest to reduce drug prices is heating up. But will he be able to do it?
President Donald Trump is ramping up the heat on pharmaceutical companies, urging them in letters sent Thursday to cut down drug prices in accordance with an executive order he signed in May. But Trump has limited authority to actually force drug companies to adjust prices, according to experts, and his effort equates to price control. As a result, utilizing public pressure through these letters may be one tool he's employing to get companies to comply, according to Benedic Ippolito, a senior fellow in economic policy studies at the conservative-leaning American Enterprise Institute think tank. "One of the big questions has been just how much can the administration realistically pressure these drugmakers to do something that is at least nominally voluntary," Ippolito told Fox News Digital Monday. Drug prices have dramatically climbed in recent years. Prescription drug prices increased more than 15% from January 2022 and January 2023, reaching an average of $590 per drug product, according to the Department of Health and Human Services. Of the 4,200 prescription drugs included on that list, 46% of the price increases exceeded the rate of inflation. Trump's original executive order signed in May directs the Department of Health and Human Services to establish price targets for pharmaceutical manufacturers. Failure to comply will prompt the Justice Department and the Federal Trade Commission to "undertake enforcement action against any anti-competitive practices," along with other consequences. Additionally, Trump introduced plans to launch "most favored nations drug pricing." "The principle is simple – whatever the lowest price paid for a drug in other developed countries, that is the price that Americans will pay," Trump said at the White House in May upon signing the order. "Some prescription drug and pharmaceutical prices will be reduced almost immediately by 50 to 80 to 90%." "We're going to equalize," Trump said. "We're all going to pay the same. We're going to pay what Europe pays." However, Ippolito said Trump's ability to actually lower the cost of drugs will be dependent on the administration's ability to present drug companies with a "credible threat" to pressure them into submission. "The administration, realistically, does not have a ton of leverage to force drugmakers to change their behavior," Ippolito said. "I think that's the practical reality." Additionally, Ippolito said Congress has greater authority to establish new laws that would have "profound implications for drug markets." But Trump's views on the issue may not attract support from even members of his own party, he said. "Congressional Republicans are generally more hesitant to do bold things on drug pricing, and the administration, the president, seems to have quite different views," Ippolito said. "And so I think he probably looks at Congress and sees some people who may not share his vision on this particular issue." Michael Cannon, director of health policy studies at the Washington-based libertarian-leaning Cato Institute think tank, said the effort amounts to price controls since the executive order isn't limited to government programs – it applies to the free market and private sector as well. "This is government price controls," Cannon told Fox News Digital Monday. "It is even worse than government price controls, because it is government price controls without Congress' permission." Price control occurs when the government steps in to impose limits on how much one can charge for various goods or services in the free market. While price controls may lower costs for some consumers, they have largely been ineffective in American history. For example, President Richard Nixon implemented price controls in the 1970s in an attempt to fix wages and other costs – which backfired and resulted in the gas crisis and other shortages across the country. Meanwhile, Cannon said there are plenty of other avenues that could lead to reduced drug prices, including reforms to Medicaid, Medicare and the tax code. But all those options would involve the legislative branch. "Those things require Congress, for the most part, and it's hard to get anything through Congress that would reduce wasteful spending in the health sector," Cannon said. The White House sent letters to the following drug companies Thursday, advocating for lower drug prices: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi.
Yahoo
32 minutes ago
- Yahoo
Legionnaires' disease cluster in New York City causes 2 deaths, sickens 58 people. What is it, and how do you get it?
The disease was initially detected on July 25. Two people have died and 58 people have been sickened in a Legionnaires' disease cluster in central Harlem in New York City, health officials said Monday. The disease was initially detected on July 25. Since then, the New York City Department of Health has been investigating the cluster and has sampled all cooling towers within the affected area, which help regulate a building's temperature. Eleven cooling towers tested positive for the bacteria that cause Legionnaires' disease. The remediation required by the health department has been completed, according to a Monday update. The following ZIP codes and bordering communities have been affected in Harlem: 10027, 10030, 10035, 10037 and 10039. "Anyone in these ZIP codes with flu-like symptoms should contact a health care provider as soon as possible," said acting health commissioner Dr. Michelle Morse. "Legionnaires' disease can be effectively treated if diagnosed early, but New Yorkers at higher risk, like adults aged 50 and older and those who smoke or have chronic lung conditions, should be especially mindful of their symptoms and seek care as soon as symptoms begin." What is Legionnaires' disease? It's a serious type of pneumonia, a lung infection, that is caused by Legionella bacteria. People can become sick from inhaling water vapor that's contaminated with Legionella bacteria. Less commonly, a person can get sick when water contaminated with the bacteria accidentally enters the lungs by aspiration. How does it spread? In general, Legionnaires' is not transmitted from person to person. Legionella can grow and spread in human-made water systems like showerheads and sink faucets, hot tubs, decorative fountains, complex and large plumbing systems and cooling towers, according to the Centers for Disease Control and Prevention. There are also factors that make it easier for Legionella to grow and survive in water, including: Biofilm, which is slime that enables germs to grow Temperatures from 77 degrees to 113 degrees Fahrenheit Not having enough disinfectant Slow or no water movement (Read more from the CDC about how to prevent waterborne germs while away from your home.) What are the symptoms of Legionnaires' disease? Symptoms usually appear in a person within two to 14 days after they've been exposed to the bacteria, the CDC says. Symptoms can be similar to other types of pneumonia, such as: Headache Muscle aches Shortness of breath Cough Fever Other symptoms can include confusion, diarrhea or nausea. Who is at risk of getting sick? Most healthy people exposed to Legionella don't become ill, according to the CDC's website. However, the following people are at increased risk of getting sick from the bacteria: People 50 years and older Current or former smokers People with specific health issues or conditions, like cancer, chronic lung disease, diabetes, kidney failure, liver failure and a weak immune system Diagnosis and treatment A chest x-ray can confirm if a person has pneumonia. But additional tests are needed to confirm if Legionella bacteria is the cause behind it, such as a urine test, or a lab test involving a sample from phlegm (sputum) or lung lavage (lung washing), according to the CDC. The disease is treatable with antibiotics, but hospital care is often needed.
